BENBROOK, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) — Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company’s financial results for the fourth fiscal quarter and full year 2025. Highlights from 2025:Revenues were $76.3 million, up 2.6% from 2024 Generated operating loss of $1.0 million versus income of $0.6 million in 2024 Net income of $9.1 million versus $0.8 million in 2024 Gross margins of 57.0%, up from 56.2% in 2024 Operating expenses $44.5 million, up 8.1% from 2024 Adjusted EBITDA* (from operations) of $0.6 million Ended year with $16.1 million of cash and cash equivalentsTandy Leather Factory’s fourth quarter sales were $22.2 million in 2025, up from $20.5 million in 2024. Fourth quarter 2025 gross profit was $12.1 million, up from $10.8 million in 2024. As of December 31, 2025, the Company held $16.1...

Tonner Drones concludes transition year with €1.1M net profit Paris, February 24th, 2026, 18:30, Tonner Drones (’the Company’) is pleased to announce its 2025 results. The year ended with a net profit of €1.1 million. Furthermore, equity was strengthened by more than €6 million, allowing the company to report positive equity. Tonner Drones had a successful year, completing its reorganization and refinancing. The company is pleased to announce that it has succeeded in its plan to prepare for renewed growth. Tonner Drones strives for continued profitability and value creation for shareholders in 2026. In the figures for 2025, only turnover declined, all other results improved.        Operating expenses(€778k) still included items related to the reorganization and refinancing, such as costs for corporate actions and legal costs. Tonner Drones...

2025 results in line with guidanceLaunch of Horizons strategic plan Paris, February 24th, 2026 – Ipsos, one of the world’s leading market research and opinion polling companies, today announces its full-year 2025 results. Revenue, organic growth and operating margin rate, communicated on a preliminary basis at the Investor Day on 22 January, are confirmed.Revenue: €2,525 millionTotal growth: +3.4% Organic growth: +0.6%Operating margin: €309 millionOperating margin rate: 12.3% Operating margin rate at constant scope*: 12.8%*Excluding temporarily dilutive effect related to The BVA Family and infas acquisitions Ipsos recorded revenue of €2,524.7 million in 2025, up 3.4%, including 0.6% organic growth, a 5.8% scope effect mainly related to the acquisitions of The BVA Family and infas, and a negative 3.0% foreign...

Clichy, France – February 24, 2026 FULL YEAR 2025 RESULTS Challenging year in 2025 with an improved momentum in the second half. Resilient free cash flow generation Renewed governance and executive leadership team to lead BIC’s next phase of growth Initial strategic actions launched in H2 2025 to streamline the portfolio FY net sales of €2,090m, -0.9% at constant currency (-4.7% on a comparative basis1), in a particularly challenging US environment. Q4 net sales of €495m, +1.1% at constant currency (-2.3% on a comparative basis1) with robust performance of Tangle Teezer as well as strong growth in Brazil and Middle East and Africa. 2025 adjusted EBIT of €283m (vs. €343m in 2024), adjusted EBIT margin of 13.6% reflecting a decline in gross profit margin, partially offset by some cost control. 2025 adjusted EPS at €4.74 (vs. €6.15 in 2024). Resilient...

Total revenues increased 20.3% to $1.2 billion, with System-wide sales up 16.1% to $1.4 billion Income from operations margin of 2.3% and Restaurant level operating profit margin of 18.5% Net income of $19.4 million and Adjusted EBITDA of $120.9 million 64 system-wide restaurants opened across 23 statesBRADENTON, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended December 28, 2025 (“Q4 2025”) and the 52-week fiscal year ended December 28, 2025 (“2025”) compared to the thirteen weeks ended December 29, 2024 (“Q4 2024”) and the 52-week fiscal year ended December 29, 2024 (“2024”) and provided an outlook for the 52-week fiscal...

KUALA LUMPUR, Malaysia, Feb. 24, 2026 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company, today announced its financial results for the second quarter ended December 31, 2025. Key Financial HighlightsRevenue for the second quarter was USD1.08 million, a significant increase from USD0.30 million in Q2 FY2025, driven by continued growth in gift-card (“E-voucher”) transactions on the ZCITY platform. Net loss was USD3.11 million, compared to USD0.23 million in Q2 FY2025, partially offset by USD4.63 million in favorable fair-value adjustments of derivative liabilities. Loss per share was USD(3.47), compared to USD(11.32) in Q2 FY2025 (retroactively adjusted for stock splits). Cash and cash equivalents increased to USD5.45 million, up from USD0.24...

OAK BROOK, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) — Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the fourth quarter and fiscal year ended December 28, 2025. Fourth Quarter 2025 Performance Highlights (vs. Fourth Quarter 2024):Total revenue of $185.7 million, an increase of 0.6% or $1.1 million Same-restaurant sales decrease of -3.3% Operating income of $10.3 million, a decrease of $3.5 million Net income of $6.3 million, a decrease of $6.2 million Restaurant-Level Adjusted EBITDA(1) of $40.6 million, a decrease of $4.7 million Adjusted EBITDA(1) of $24.7 million, a decrease of $0.5 millionFiscal 2025 Performance Highlights (vs. Fiscal 2024):Total revenue of $732.1 million, an increase of...

Positive human data and upcoming clinical catalysts across portfolio SOLANA BEACH, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2025. Business Highlights: Successful Phase 1 study with ART26.12: Reported positive first-in-human Phase 1 single ascending dose (SAD) clinical data demonstrating a favorable safety profile, predictable pharmacokinetics, and dosing flexibility. As a result, the Company is working to complete preparations to open enrollment to the...

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter Full year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVID Full year 2026 revenue guidance of $810 million – $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpointWALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve- month periods ended December 31, 2025. The Company is also providing financial guidance for the full year 2026. Olivier Loeillot, President...

– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 – $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million –      – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) —  – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported fourth quarter and full year 2025 financial results and recent portfolio execution. “Kiniksa...